PURPOSE: We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced non-small-cell lung cancer and in patients treated at a tertiary cancer center. PATIENTS AND METHODS: We monitored symptom severity weekly during chemotherapy. Patients were recruited from a tertiary cancer center (n=101) and three public hospitals treating the medically underserved (n=80). We used a composite symptom-severity score and group-based trajectory analysis to form two groups: one with consistently more severe symptoms and another with less severe symptoms. We examined predictors of group membership. RESULTS: Seventy percent of the sample (n=126) reported low symptom-severity levels that decreased during therapy; 30% (n=55) had consistently severe symptoms throughout the study. In multivariate analysis, patients with good performance status being treated in public hospitals were significantly more likely than patients treated at the tertiary cancer center to be in the high-symptom group (odds ratio, 5.6; 95% CI, 2.1 to 14.6; P = .001) and to report significantly higher symptom interference (P = .001). Other univariate predictors of high-symptom group membership included variables associated with being medically underserved (eg, having less education, being single, and being nonwhite). No group differences by ethnicity were observed in the public hospitals. Medically underserved patients were less likely to receive adequate pain management. CONCLUSION: Patients with advanced lung cancer and good performance status treated at public hospitals were more likely than those treated at a tertiary cancer center to experience substantial symptoms during chemotherapy.
PURPOSE: We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced non-small-cell lung cancer and in patients treated at a tertiary cancer center. PATIENTS AND METHODS: We monitored symptom severity weekly during chemotherapy. Patients were recruited from a tertiary cancer center (n=101) and three public hospitals treating the medically underserved (n=80). We used a composite symptom-severity score and group-based trajectory analysis to form two groups: one with consistently more severe symptoms and another with less severe symptoms. We examined predictors of group membership. RESULTS: Seventy percent of the sample (n=126) reported low symptom-severity levels that decreased during therapy; 30% (n=55) had consistently severe symptoms throughout the study. In multivariate analysis, patients with good performance status being treated in public hospitals were significantly more likely than patients treated at the tertiary cancer center to be in the high-symptom group (odds ratio, 5.6; 95% CI, 2.1 to 14.6; P = .001) and to report significantly higher symptom interference (P = .001). Other univariate predictors of high-symptom group membership included variables associated with being medically underserved (eg, having less education, being single, and being nonwhite). No group differences by ethnicity were observed in the public hospitals. Medically underserved patients were less likely to receive adequate pain management. CONCLUSION:Patients with advanced lung cancer and good performance status treated at public hospitals were more likely than those treated at a tertiary cancer center to experience substantial symptoms during chemotherapy.
Authors: Tito R Mendoza; Xin Shelley Wang; Charles Lu; Guadalupe R Palos; Zhongxing Liao; Gary M Mobley; Shitij Kapoor; Charles S Cleeland Journal: Oncologist Date: 2011-02-01
Authors: Xin Shelley Wang; Charles S Cleeland; Tito R Mendoza; Young Ho Yun; Ying Wang; Toru Okuyama; Valen E Johnson Journal: J Natl Cancer Inst Date: 2010-03-26 Impact factor: 13.506
Authors: C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya Journal: N Engl J Med Date: 1994-03-03 Impact factor: 91.245
Authors: Xin Shelley Wang; Qiuling Shi; Charles Lu; Ethan M Basch; Valen E Johnson; Tito R Mendoza; Gary M Mobley; Charles S Cleeland Journal: Cancer Date: 2010-01-01 Impact factor: 6.860
Authors: Donald L Patrick; Sandra L Ferketich; Paul S Frame; Jesse J Harris; Carolyn B Hendricks; Bernard Levin; Michael P Link; Craig Lustig; Joseph McLaughlin; L Douglas Ried; Andrew T Turrisi; Jürgen Unützer; Sally W Vernon Journal: J Natl Cancer Inst Date: 2003-08-06 Impact factor: 13.506
Authors: Desiree Jones; Elisabeth G Vichaya; Charles S Cleeland; Lorenzo Cohen; Seema M Thekdi; Xin Shelley Wang; Michael J Fisch Journal: J Oncol Pract Date: 2013-11-26 Impact factor: 3.840
Authors: Qiuling Shi; Tito R Mendoza; G Brandon Gunn; Xin Shelley Wang; David I Rosenthal; Charles S Cleeland Journal: Qual Life Res Date: 2013-03-09 Impact factor: 4.147
Authors: Bradley J Barney; Xin Shelley Wang; Charles Lu; Zhongxing Liao; Valen E Johnson; Charles S Cleeland; Tito R Mendoza Journal: Qual Life Res Date: 2013-01-31 Impact factor: 4.147
Authors: Donna S Zhukovsky; Cathy L Rozmus; Rhonda S Robert; Eduardo Bruera; Robert J Wells; Gary B Chisholm; Julio A Allo; Marlene Z Cohen Journal: Cancer Date: 2015-07-28 Impact factor: 6.860
Authors: Christopher Fagundes; Desiree Jones; Elisabeth Vichaya; Charles Lu; Charles S Cleeland Journal: J Thorac Oncol Date: 2014-10 Impact factor: 15.609